Cite
HARVARD Citation
Furie, R. et al. (n.d.). SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le. Annals of the rheumatic diseases. p. 857. [Online].